参考文献/References:
[1] Lambrecht FY,Durkan K,Yildirim Y,et al.Labeling of acetaminophen with 1-131 and biodistribution in rats[J].Chem Pharm Bull (Tokyo),2006,54(2):245-247.
[2] Panjideh H,Da Silva Coelho VC,Demedde J,et al.Biodistribution and efficacy of [131I]A33scFv:CDy,a recombinant antibody-enzyme protein for colon cancer[J].Int J Oncol,2008,32(4):925-930.
[3] Stein R,Govindan SV,Hayes M,et al.Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcino embryonic antigen monoclonal antibody[J].Clin Cancer Res,2005,11(7):2727-2734.
[4] Reist CJ,Archer GE,Kurpad SN,et al.Tumor-specific antiepidermal growth factor receptor variant III monoclonal antibodies:use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts[J].Cancer Res,1995,55(19):4375-4382.
[5] Gereben B,Zeold A,Dentice M,et al.Activation and inactivation of thyroid hormone by deiodinases:Local action with general consequences[J].Cell Mol Life Sci,2008,65(4):570-590.
[6] Köhrle J.Thyroid hormone metabolism and action[J].Z Arztl Fortbild Qualitatssich,2004,98(Suppl 5):17-24.
[7] Bianco AC,Larsen PR.Cellular and structural biology of the deiodinases[J].Thyroid,2005,15(8):776-786.
[8] Pujals S,Fernandez-Carneado J,Ludevid MD,et al.D-SAP:a new,noncytotoxie,and fully protease resistant cell-penetrating peptide[J].ChemMedChem,2008,3(2):296-301.
[9] Govindan SV,Stein R,Qu Z,et al.Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody:advantage of a residualizing iodine radiolabel[J].Breast Cancer Res Treat,2004,84(2):173-182.
[10] Stein R,Govindan SV,Mattes M J,et al.Improved iodine radiolabels for monoclonal antibody therapy[J].Cancer Res,2003,63(1):111-118.
[11] Holmberg M,Stibius KB,Ndoni S,et al.Protein aggregation and degradation during iodine labeling and its consequences for protein adsorption to biomaterials[J].Anal Biochem,2007,361(1):120-125.
[12] Hayes DF,Noska MA,Kufe DW,et al.Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells[J].Nucl Med Biol,1988,15(3):235-241.
[13] Song SH,Jung KH,Paik JY,et al.Distribution and pharmaeokinetie analysis of angiostatin radioiodine labeled with high stability[J].Nuel Med Biol,2005,32(8):845-850.
[14] Bolton AE,Hunter WM.The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent[J].Biochem J,1973,133(3):529-539.
[15] Vaidyanathan G,Zalutsky MR.Preparation of N-succinimidyl 3-[*I]iodobenzoate:an agent for the indirect radioiodination of proteins[J].Nat Protoc,2006,1(2):707-713.
[16] Zalutsky MR,Xu FJ,Yu Y,et al.Radioiodinated antibody targeting of the HER-2/neu oncoprotein:effects of labeling method on cellular processing and tissue distribution[J].Nucl Med Biol,1999,26(7):781-790.
[17] Reist C J,Garg PK,Alston KL,et al.Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate[J].Cancer Res,1996,56(21):4970-4977.
[18] Michihara A,Toda K,Kubo T,et al.Disruptive effect of chloroquine on lysosomes in cultured rat hepatocytes[J].Biol Pharm Bull,2005,28(6):947-951.
[19] Shankar S,Vaidyanathan G,Kuan CT.Antie pidermal growth factor variant III scFv fragment:effect of radioiodination method on tumor targeting and normal tissue clearance[J].Nucl Med Biol,2006,33(1):101-110.
[20] Vaidyanathan G,Affleck DJ,Bigner DD,et al.Improved xenograft targeting of tumor-speeific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomet-hyl-3-iodobenzoate[J].Nucl Med Biol,2002,29(1):1-11.
[21] Shankar S,Vaidyanathan G,Affleck D J,et al.Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB),a negatively charged substituent bearing acylation agent[J].Nucl Med Biol,2004,31(7):909-919.
[22] Foulon CF,Welsh PC,Bigner DD,et al.Positively charged templates for labeling internalizing antibodies:comparison of Nsuccinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR[J].Nucl Med Biol,2001,28(7):769-777.
[23] Foulon CF,Reist CJ,Bigner DD,et al.Radioiodination via Damino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody[J].Cancer Res,2000,60(16):4453-4460.
[24] Kobayashi H,Le N,Kim IS,et al.The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points[J].Cancer Res,1999,59(2):422-430.
[25] Jones-Wilson TM,Deal KA,Anderson CJ,et al.The in vivo behavior of Copper-64-1abeled azamacrocyclic complexes[J].Nucl Med Biol,1998,25(6):523-530.
[26] Akizawa H,Uehara T,Arano Y.Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins[J].Adv Drug Delive Rev,2008,60(12):1319-1328.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]解朋,黄建敏,张芳,等.99Tcm-MAG3-isoDGR-2C分子探针的制备与体内分布的实验研究[J].国际放射医学核医学杂志,2016,40(5):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
Xie Peng,Huang Jianmin,Zhang Fang,et al.Labeling MAG3-isoDGR-2C with 99Tcm and its biodistribution in mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
[6]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[7]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]洪智慧,周小林,石怡珍,等.131I标记抗胃泌素释放前体单链抗体的制备及其稳定性和免疫活性研究[J].国际放射医学核医学杂志,2010,34(2):107.[doi:10.3760/cma.j.issn.1673-4114.2010.02.013]
HONG Zhi-hui,ZHOU Xiao-lin,SHI Yi-zhen,et al.Preparation and evaluation of 131I-anti-ProGRP(31-98) single-chain antibody fragment[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(5):107.[doi:10.3760/cma.j.issn.1673-4114.2010.02.013]
[12]苏燕,王峰,王自正,等.131Ⅰ-Tyr-octreotide的标记方法学及其生物学分布的研究[J].国际放射医学核医学杂志,2007,31(5):257.
SU Yan,WANG Feng,WANG Zi-zheng,et al.abeling mothod and biodistribution of 131Ⅰ-Tyr-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(5):257.